Research stack

PT-141 Melanocortin Sexual Response Protocol

PT-141 (bremelanotide) protocol characterized in the RECONNECT trials.

Component peptides

PT-141 (bremelanotide) protocol for melanocortin-mediated sexual response.

PT-141 activates central melanocortin-4 receptors, driving downstream dopaminergic pathways involved in sexual arousal and desire.

PT-141 — 1.75 mg subcutaneous on demand, at least 45 minutes prior to anticipated activity; maximum eight doses per month.

Last updated: 2026-09-15

Component peptides	PT-141
Duration reported	4 weeks
Cycle pattern	On-demand dosing
Difficulty	foundational
Regulatory status	Research use only. None of these compounds is FDA-approved for combined use described.

Peptide Codex Assistant

Research-literature companion

Hello. Ask me about a peptide, a stack, or a research protocol on Peptide Codex.

0 / 20 questions used todayResearch use only. Not medical advice.